Vaccines - Bolivia

Bolivia

The Vaccines market in Bolivia is projected to reach a revenue of US$32.70m by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of -3.56%, leading to a market volume of US$27.28m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue, amounting to US$29,120.00m in 2024.
Bolivia's vaccine market is experiencing a surge in demand as the government prioritizes immunization efforts to combat infectious diseases.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Bolivia has been on the rise in recent years.

Customer preferences: Bolivians have become increasingly aware of the importance of vaccination in preventing diseases. As a result, there has been a growing demand for vaccines in the country. The government has also been actively promoting vaccination programs to increase the vaccination coverage rate.

Trends in the market: The vaccines market in Bolivia has been growing steadily in recent years. There has been a significant increase in the demand for vaccines, especially for diseases such as measles, rubella, and polio. The demand for influenza vaccines has also been on the rise due to the seasonal outbreaks of the flu.

Local special circumstances: Bolivia is a developing country with a significant portion of the population living in poverty. This has led to a lack of access to healthcare facilities in many parts of the country. The government has been working to improve the healthcare infrastructure in the country, but there is still a long way to go. As a result, the demand for vaccines has been higher in urban areas where healthcare facilities are more accessible.

Underlying macroeconomic factors: The Bolivian economy has been growing steadily in recent years, which has led to an increase in disposable income for many Bolivians. This has allowed more people to afford healthcare services, including vaccinations. The government has also been investing in the healthcare sector, which has led to an improvement in the quality of healthcare services in the country. Additionally, the government has been providing subsidies for vaccines, which has made them more affordable for the general population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.